Why GLP-1 Drugs May Need Glucagon to Boost Metabolism for Better Weight Loss
GLP-1 drugs suppress appetite but don't increase energy expenditure — adding glucagon receptor activation could close this metabolic gap for more effective obesity treatment.
Quick Facts
What This Study Found
Glucagon receptor agonism increases lipid oxidation, substrate mobilization, and energy expenditure, complementing GLP-1R appetite suppression and potentially overcoming adaptive metabolic decline during weight loss.
Key Numbers
How They Did This
Narrative review integrating historical, preclinical, and clinical evidence on glucagon as a regulator of energy expenditure and its therapeutic potential alongside GLP-1 agonism.
Why This Research Matters
The metabolic slowdown during weight loss is a major reason people plateau or regain weight. Adding glucagon receptor activation could be the key to sustaining weight loss long-term.
The Bigger Picture
This explains the rationale behind next-generation triple agonists (GLP-1/GIP/glucagon) like retatrutide and survodutide that are showing unprecedented weight loss in clinical trials.
What This Study Doesn't Tell Us
Review article — no new experimental data. Glucagon's hyperglycemic effects pose safety challenges that need to be balanced against metabolic benefits.
Questions This Raises
- ?Can the EE-boosting effects of glucagon be separated from its blood sugar-raising effects?
- ?Will triple agonists including glucagon produce more durable weight loss than GLP-1 alone?
Trust & Context
- Key Stat:
- Energy expenditure gap GLP-1 drugs suppress appetite but don't prevent the metabolic slowdown that limits long-term weight loss
- Evidence Grade:
- Narrative review integrating preclinical and clinical evidence — provides strong mechanistic rationale but no new trial data.
- Study Age:
- Published in 2026; directly relevant to next-generation obesity drugs in development.
- Original Title:
- GLP-1 is not enough: can glucagon fill the energy expenditure gap?
- Published In:
- Neuroendocrinology, 1-26 (2026)
- Authors:
- Beji, Sarra, Caron, Alexandre(2)
- Database ID:
- RPEP-14856
Evidence Hierarchy
Frequently Asked Questions
Why does metabolism slow during weight loss?
When you lose weight, your body adapts by burning fewer calories — this is called adaptive thermogenesis. It's a survival mechanism that makes continued weight loss harder and promotes weight regain.
What are triple agonist drugs?
Triple agonists target three hormone receptors (GLP-1, GIP, and glucagon) simultaneously. By combining appetite suppression with increased energy burning, they may produce more weight loss than current drugs like semaglutide or tirzepatide.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14856APA
Beji, Sarra; Caron, Alexandre. (2026). GLP-1 is not enough: can glucagon fill the energy expenditure gap?. Neuroendocrinology, 1-26. https://doi.org/10.1159/000550812
MLA
Beji, Sarra, et al. "GLP-1 is not enough: can glucagon fill the energy expenditure gap?." Neuroendocrinology, 2026. https://doi.org/10.1159/000550812
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 is not enough: can glucagon fill the energy expenditur..." RPEP-14856. Retrieved from https://rethinkpeptides.com/research/beji-2026-glp1-is-not-enough
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.